During 2012, the Chilean Antitrust case denominated “Pharmacies” became one of the leading in terms of investigation conducted by the Fiscalia Nacional Economica and one of the highlighted decisions of the Antitrust Court, Tribunal de Defensa de la Libre Competencia. This paper analyses the basic structure of judgement 119/2012 issued by the Tribunal, and confirmed by Chilean Supreme Court, by decision 2578-2012, which it was written by judge Sergio Muñoz, rejecting an appeal issued by Cruz Verde S.A and Salcobrand S.A. The article also studies the way by which the judges define the relevant market, and discusses some elements about parallel pricing. Furthermore, the case was controversial with respect to to the application of an agreement of conciliation with FASA S.A.
Full Content: SSRN
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Subscribers Defend $4.7 Billion Antitrust Verdict Against NFL in Court Filings
Jul 19, 2024 by
CPI
Von der Leyen Calls for Competition Policy to Boost EU Companies’ Growth
Jul 19, 2024 by
CPI
Vermont AG Sues Pharmacy Benefit Managers Over Drug Prices
Jul 18, 2024 by
CPI
Australians Face Increased Stamp Prices Following ACCC Approval
Jul 18, 2024 by
CPI
Live Nation Seeks Dismissal of DOJ Antitrust Allegations
Jul 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Private Equity Roll-Up Schemes
Jun 28, 2024 by
CPI
The FTC’s Focus on Private Equity is Warranted
Jun 28, 2024 by
CPI
Unraveling the Roll-Up: Private Equity’s Misunderstood Investment Strategy
Jun 28, 2024 by
CPI
Antitrust Focus on Private Equity Funds and Serial Acquisitions
Jun 28, 2024 by
CPI
Private Equity Roll-Ups Amidst Heightened Antitrust Enforcement
Jun 28, 2024 by
CPI